First Trust NASDAQ Clean Edge Green Energy Idx Fd vs Tempus AI — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $49.69 (market cap $561.25M), while Tempus AI trades at $69.85 (market cap $12.58B). The key difference: Tempus AI is far larger — about 22.4× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Tempus AI is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days and Tempus AI for 22 Days on average.
| QCLN | TEM | |
|---|---|---|
Market Cap | $561.25M | $12.58B |
Volume | 323,550 | 7,444,569 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $68.47 | $99.28 |
52-Week Low | $41.10 | $41.55 |
Typical Hold Time | 50 Days | 22 Days |
Enterprise Value | — | $13.21B |
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $49.44, down 2.62% today but maintains a bullish technical outlook with strong moving average support. The clean energy ETF benefits from geopolitical tensions accelerating renewable energy adoption globally. Recent news highlights increased data center energy demand and political focus on clean energy policies as key growth catalysts.
The ETF's performance remains tied to U.S. political outcomes and federal energy policy, with recent outperformance against major indices. Key risks include policy uncertainty and market volatility, while institutional interest grows amid global energy security concerns and the ongoing energy transition.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →